Clinical trials: CBD
Posttraumatic Stress Disorder
Pilot Study of the Safety and Efficacy of Four Different Potencies of Smoked Marijuana in 76 Veterans With PTSD
This pilot study gathered preliminary evidence of the safety and efficacy of four potencies of smoked cannabis to manage chronic, treatment-resistant PTSD among veterans: (1) High THC/ Low CBD (High THC), (2) Low THC/High CBD…
- Trial name
- NCT02759185
- Testing
- High THC cannabis, High CBD cannabis, THC/CBD cannabis
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Multidisciplinary Association for Psychedelic Studies
Parkinson's Disease
Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy
The CELC200A2401 study has been designed in order to evaluate the hypothesis that administering the combination carbidopa/levodopa/entacapone at the time that levodopa therapy is initiated results in a decrease in the risk of the…
- Trial name
- STRIDE-PD (NCT00099268)
- Testing
- Carbidopa/levodopa/entacapone, Immediate release carbidopa/levodopa
- Where
- 73 sites in United States, Austria and 12 more
- Volunteers
- 747 people
- Sponsor
- Novartis Pharmaceuticals
Schizophrenia, Schizoaffective Disorder
Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia
This study is a six-week, randomized, placebo-controlled, fixed dose trial comparing cannabidiol Vs. placebo added to a stable dose of antipsychotic medications in patients diagnosed with schizophrenia.
- Trial name
- NCT00588731
- Testing
- Cannabidiol
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Yale University
Acne Vulgaris
Evaluation of BTX 1503 in Patients With Moderate to Severe Acne Vulgaris
The objective of this study is to assess safety and efficacy of various doses of BTX 1503 liquid formulation in subjects with moderate to severe acne vulgaris of the face.
- Trial name
- NCT03573518
- Testing
- BTX 1503, Vehicle
- Where
- 36 sites in United States, Australia
- Volunteers
- 368 people
- Sponsor
- Botanix Pharmaceuticals
Essential Tremor
Trial of Cannabis for Essential Tremor
This is a pilot trial to evaluate the safety and efficacy of a combined oral formulation of THC and CBD in patients with Essential Tremor.
- Trial name
- NCT03805750
- Testing
- CBD/THC
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of California, San Diego
Smoking, Marijuana
Laboratory Study of Cannabidiol on the Effects of Smoked Marijuana
The objective of this study is to assess the effects of oral cannabidiol (CBD; 0, 200, 400, 800 mg) on smoked marijuana's (0, 5.6% THC) subjective, reinforcing, cognitive, and cardiovascular effects.
- Trial name
- NCT01844687
- Testing
- CBD
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- National Institute on Drug Abuse (NIDA)
Prader-Willi Syndrome
Cannabidiol Oral Solution for the Treatment of Patients With Prader-Willi Syndrome
The primary objective of this study is to assess the efficacy of cannabidiol oral solution on hyperphagia-related behavior in patients with Prader-Willi Syndrome (PWS).
- Trial name
- NCT02844933
- Testing
- Cannabidiol
- Where
- 7 sites in United States
- Volunteers
- 7 people
- Sponsor
- Radius Pharmaceuticals, Inc.
Rett Syndrome, RTT
Efficacy and Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome
To evaluate the efficacy of cannabidiol oral solution (GWP42003-P, CBD-OS) in reducing symptom severity when compared with placebo, in participants with Rett syndrome.
- Trial name
- ARCH (NCT03848832)
- Testing
- GWP42003-P
- Where
- 26 sites in United States, Italy and 2 more
- Volunteers
- 29 people
- Sponsor
- Jazz Pharmaceuticals
Lennox-Gastaut Syndrome, Dravet Syndrome
The Effects of Cannabidiol (CBD) on Electrical and Autonomic Cardiac Function in Children With Severe Epilepsy
The investigators propose to study the effects of cannabidiol (CBD) on cardiac electrical function and the autonomic nervous system in children with Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS), when the CBD is…
- Trial name
- CBD1 (NCT02815540)
- Testing
- 12-Lead ECG, Cannabidiol
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Gillette Children's Specialty Healthcare
Parkinson's Disease
Duodopa Home Titration Using Telemedicine: Evaluation of Use of Resources
The purpose of this study was to evaluate the use of resources during titration of Duodopa at home.
- Trial name
- NCT01956032
- Volunteers
- 15 people
- Sponsor
- AbbVie
Angelman Syndrome
A Trial of Levodopa in Angelman Syndrome
This study is designed to determine whether levodopa will lead to an improvement in the development and tremor in children with Angelman syndrome (AS).
- Trial name
- NCT01281475
- Testing
- Levodopa
- Where
- 7 sites in United States
- Volunteers
- 67 people
- Sponsor
- Wen-Hann Tan
Alcohol Use Disorder
Effects of Cannabidiol in Alcohol Use Disorder
The goal of the proposed project is to begin rigorous study of the clinically relevant effects of non-psychoactive phytocannabinoid cannabidiol (CBD) in patients with severe alcohol use disorder (AUD).
- Trial name
- NCT03252756
- Testing
- Phytocannabinoid cannabidiol (CBD)
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- NYU Langone Health
Familial Dysautonomia
Carbidopa for the Treatment of Nausea and Vomiting in Familial Dysautonomia
This is a pilot clinical trial of carbidopa to treat disabling attacks of nausea and vomiting in patients with familial dysautonomia (FD, also known as Riley Day syndrome or hereditary sensory and autonomic neuropathy type III).
- Trial name
- NCT01212484
- Testing
- Carbidopa
- Volunteers
- 12 people
- Sponsor
- NYU Langone Health
Parkinson's Disease (Disorder)
A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Participants With Motor Fluctuations
To evaluate the safety and efficacy of IPX203 (carbidopa and levodopa) extended-release capsules (IPX203 ER CD-LD) in comparison to immediate release (IR) CD-LD in the treatment of CD-LD-experienced participants with Parkinson's…
- Trial name
- NCT03670953
- Testing
- IR CD-LD, IPX203 ER CD-LD
- Where
- 108 sites in United States, Czechia and 6 more
- Volunteers
- 630 people
- Sponsor
- Impax Laboratories, LLC
Seizures Associated With EMAS
Efficacy and Safety of GWP42003-P Oral Solution in Children With Epilepsy With Myoclonic-atonic Seizures
The primary aim of Part A of the study to assess the efficacy and tolerability of GWP42003-P compared to placebo as an adjunctive treatment for children with Epilepsy with myoclonic-atonic seizures (EMAS) -associated seizures.
- Trial name
- NCT05288283
- Testing
- GWP42003-P
- Where
- 14 sites in United States, Italy
- Volunteers
- 3 people
- Sponsor
- Jazz Pharmaceuticals
Parkinson's Disease
Global REsponsE During iNFusIon of a gEl With LevoDopa/Carbidopa
This multicenter, post marketing observational study (PMOS) was designed to evaluate the long-term effectiveness of levodopa/carbidopa intestinal gel (DUODOPA) on motor fluctuations (duration of OFF periods) in participants with…
- Trial name
- GREENFIELD (NCT01754129)
- Volunteers
- 148 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Cannabidiol, Drug Induced Liver Injury
Clinical Study to Evaluate Cannabidiol Liver Enzyme Elevations and Drug Interactions
Cannabidiol (CBD) is available as a prescription drug product for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex.
- Conditions
- Cannabidiol, Drug Induced Liver Injury, Drug Interaction
- Trial name
- NCT06192589
- Testing
- Cannabidiol, Citalopram, Morphine
- Where
- United States
- Volunteers
- 241 people, healthy volunteers welcome
- Sponsor
- Food and Drug Administration (FDA)
Opioid Use Disorder
Cannabidiol in the Treatment of Opioid Use Disorder
The long-term goal of the project is to determine whether cannabidiol (CBD) can reduce craving and relapse in individuals with opioid use disorder (OUD).
- Trial name
- NCT06206291
- Testing
- Cannabidiol (CBD) 200mg, Cannabidiol (CBD) 400mg
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- Yasmin Hurd
Opioid-use Disorder
Cannabidiol Use to Reduce Cravings in Individuals With Opioid Use Disorder on Buprenorphine
The purpose of this week-long study is to determine the impact of cannabidiol on cue-induced cravings among individuals with opioid use disorder who are stable on sublingual buprenorphine treatment.
- Trial name
- CURB (NCT04192370)
- Testing
- Cannabidiol 600mg
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Brigham and Women's Hospital
Chronic Inflammation
Single-cell CBD Biomarkers of Inflammation Reduction in People Living With HIV
People living with HIV (PLWH) are affected by comorbidities appearing to be strongly related to chronic inflammation, a condition characterizing PLWH.
- Trial name
- NCT05209867
- Testing
- CBD oil
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Florida